Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
Opus Genetics (Nasdaq: IRD) updated its OPGx-BEST1 Phase 1/2 BIRD-1 trial for BEST-1 associated inherited retinal diseases. Cohort 1 enrollment (5 participants) is complete, and three-month topline safety and OCT structural data are expected in the second week of September 2026, with presentation at EURETINA in October. IDMC will review after Month 3.
How this was made
The 30-second read
Why it matters
The company provides a detailed timeline for Cohort 1 Month 3 review and expects three-month topline data in early September 2026, with planned structural (OCT) and functional (microperimetry, BCVA, LLVA, contrast sensitivity) assessments and an FDA alignment step.
Market read
For IRD traders, the actionable element is the near-term catalyst calendar: Cohort 1 topline timing, what endpoints will be emphasized, and the quiet-period start date.
What to watch
Key risk is that Cohort 1 topline depends on participant completion and IDMC next-step decisions; any slippage or safety signals later could reverse sentiment quickly.
Background
Opus Genetics is running an adaptive, open-label Phase 1/2 trial (BIRD-1) for its AAV-based gene therapy OPGx-BEST1 in BEST-1 associated inherited retinal diseases (BVMD and ARB).
Ticker impact
Opus Genetics (IRD) set expectations for Cohort 1 three-month topline data in the second week of September 2026 and details Month 3 review steps.
Likely modest pre-data positioning into September, with volatility around any subsequent Month 3/IDMC communications.
This is a Phase 1/2 program timeline update (no new topline numbers). However, it provides specific timing, endpoints, and regulatory alignment intent (FDA discussion), which can move biotech sentiment and trading activity ahead of data.
Market effects
Adds incremental signal to the gene-therapy/inherited retinal disease pipeline calendar, potentially supporting peer sentiment around upcoming readouts.
Limited; company-specific biotech catalyst with no clear regional macro linkage.
Moderate; EURETINA timing can broaden visibility for IRD’s program among global ophthalmology investors.
Counterpoint
Because the release is primarily scheduling and protocol framing, it may not change the probability-weighted outcome versus prior expectations, limiting sustained upside.
Key entities
- companyOpus Genetics, Inc.
Clinical-stage gene therapy company developing OPGx-BEST1 for BEST-1 associated inherited retinal diseases.
- programOPGx-BEST1
AAV-based gene therapy intended to deliver a functional BEST1 gene to retinal pigment epithelium cells.
- clinical_trialBIRD-1 (Phase 1/2)
Adaptive, open-label study evaluating safety and efficacy of OPGx-BEST1 with dose escalation across cohorts.
- committeeIDMC
Independent Data Monitoring Committee that will review Cohort 1 data and determine next steps.
- regulatorFDA
Planned to receive Month 3 data to align on next clinical development steps.
